Briacell Therap (NASDAQ:BCTX) Posts Earnings Results

Briacell Therap (NASDAQ:BCTX) issued its earnings results on Tuesday. The company reported ($2.58) earnings per share for the quarter, Zacks reports.

Briacell Therap Stock Performance

Shares of BCTX stock traded up $0.32 during trading hours on Wednesday, reaching $4.13. The company had a trading volume of 83,212 shares, compared to its average volume of 569,195. The company has a market capitalization of $29.91 million, a P/E ratio of -0.09 and a beta of 1.46. Briacell Therap has a twelve month low of $3.60 and a twelve month high of $98.20. The stock’s fifty day simple moving average is $4.87 and its 200 day simple moving average is $8.20.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $320.00.

Hedge Funds Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in Briacell Therap (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is owned by institutional investors and hedge funds.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.